Concepedia

Author

Maurizio Nicodemo

Ospedale Sacro Cuore Don CalabriaORCID

Also Known As

Cecilia Nasso, M. Nicodemo, Maurizio Nicodemo, Nicodemo, Maurizio

44

Publications

263

Citations

9

H-Index

13

Concepts

All Affiliations

Ospedale Sacro Cuore Don CalabriaIstituto Oncologico VenetoIstituti di Ricovero e Cura a Carattere ScientificoIstituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriAzienda Ospedaliera Universitaria Integrata Verona
MN

About

Maurizio Nicodemo is an author at Ospedale Sacro Cuore Don Calabria specializing in urology, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

95

2

Pharmacology

2

2

45

3

Surgical Oncology

2

2

50

4

Cancer Therapeutics

2

2

38

5

Nephrology

1

1

28

Maurizio Nicodemo

×

7

Publications

165

Citations

7

H-Index

YearCitations

Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial

Umberto Basso, Antonella Facchinetti, Elisabetta Rossi,

The Oncologist

2021

38

Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series

Berardino De Bari, Rosario Mazzola, Dario Aiello,

La radiologia medica

2018

29

Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series

Gianluigi Lunardi, Andrea Armirotti, Maurizio Nicodemo,

Clinical Therapeutics

2009

28

Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region

Marco Maruzzo, Umberto Basso, Eugenio Borsatti,

Clinical Genitourinary Cancer

2018

21

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Daniele Santini, Matteo Santoni, Alessandro Conti,

Oncotarget

2016

17

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Orazio Caffo, Cinzia Ortega, Franco Nolè,

European Journal of Cancer

2021

17

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi,

BMC Medicine

2022

15

Page 1